January 2022 FDA Recall Proctofoam by Mylan Pharmaceuticals Inc
D-0452-2022 - cGMP deficiencies
This Class II drug recall was voluntarily initiated by Mylan Pharmaceuticals Inc on January 21, 2022 for the product Proctofoam. The FDA reported the reason for recall as cgmp deficiencies. The product was distributed Nationwide and the recall is currently terminated.
Recall Number: D-0452-2022
cGMP deficiencies
01-21-2022
02-02-2022
233,199/10 g aerosol containers
Recall Profile & Regulatory Data
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
The firm responsible for the recall.
Mylan Pharmaceuticals Inc
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
General area of initial distribution.
Recalled product was distributed nationwide within the United States.
03-12-2024
Product Description About Product Description
Full technical description of the product.
Full technical description of the product.
Proctofoam HC (hydrocortisone acetate 1% and pramoxine hydrochloride 1%) topical aerosol, 10 g aerosol containers, Rx Only, Distributed by Meda Pharmaceuticals Inc, Somerset, New Jersey 08873-1120, NDC 0037-6822-10.
Batch or Lot Expiration Information
Lot# : 32925, Exp. date May 2023, 33010, Exp. date June 2023; 33119, 33123, Exp. date August 2023